Eli Lilly has filed a US federal lawsuit against six companies selling products marketed as retatrutide, a medicine that has not yet been approved anywhere in the world. The case shines a direct light on the grey market for retatrutide that has grown in the UK and globally ahead of any authorised launch. Here is what the lawsuit means, and why UK readers should pay close attention.
Eli Lilly, the pharmaceutical company developing retatrutide, has filed a lawsuit in a US federal court against six companies it accuses of marketing and selling unlicensed products under the retatrutide name. According to reporting by Reuters, the case alleges trademark infringement and false advertising, among other claims. The lawsuit is significant not just as a legal dispute in the United States — it reflects a broader problem that directly affects UK consumers who have been trying to access retatrutide through unregulated channels.
What Is Retatrutide and Where Does It Currently Stand?
Retatrutide is Eli Lilly’s investigational weight-loss and metabolic medicine. Unlike Mounjaro (tirzepatide), which targets two hormone receptors, retatrutide targets three — GIP, GLP-1 and glucagon receptors simultaneously. Early clinical trial results published in The New England Journal of Medicine in 2023 showed substantial average weight loss, which attracted considerable public interest.
Crucially, retatrutide has not been approved by any medicines regulator, including the US Food and Drug Administration (FDA) or the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). It remains in Phase 3 clinical trials under Eli Lilly’s TRIUMPH programme. There is currently no MHRA-authorised retatrutide product available in the UK through any route — private or NHS.
Our full retatrutide UK guide covers the current trial status and what approval might realistically look like once it arrives.
What the Lawsuit Is Actually About
Because retatrutide has generated so much excitement ahead of its authorisation, a market has emerged in products sold online and through various clinics and compounding operations, labelled as retatrutide. Eli Lilly’s lawsuit targets six companies it says are selling these products, using its branding and trademarks without authorisation, and making misleading claims about what they are selling.
The case raises a question that matters directly to UK consumers: if a product is sold as retatrutide but there is no approved retatrutide medicine to compare it against, what exactly is in those vials or packages? The honest answer is that the identity, purity, strength and quality of any product sold as retatrutide through unregulated channels cannot be reliably verified. No independent regulatory authority has confirmed what these products contain.
Eli Lilly, as the patent holder and developer of retatrutide, has not authorised any third party to manufacture or sell the compound. The lawsuit is partly about protecting its intellectual property, but its consequence — if successful — would be to remove some of the companies currently supplying the grey market.
The UK Grey Market for Retatrutide
In the UK, a number of online sellers and some self-described research chemical or peptide suppliers have been marketing products labelled as retatrutide, typically as injectable peptides. Some have also targeted buyers through social media. The MHRA has previously issued warnings about unlicensed injectable weight-loss products more broadly, and its guidance makes clear that buying unlicensed medicines or research chemicals for self-injection carries serious risks.
UK consumers purchasing these products are not buying a medicine that has passed UK regulatory scrutiny. They are buying an unverified substance from an unregulated supply chain. The legal position for UK buyers of such products is separate from Eli Lilly’s US lawsuit, but the lawsuit does underline that even the companies supplying these products are operating outside any authorised framework.
What This Means For UK Patients
The Eli Lilly lawsuit does not directly create new legal risk for individual UK consumers, but it is a useful moment to understand what the retatrutide grey market actually is. It is not a parallel version of legitimate private prescribing — the kind that exists for Mounjaro or Wegovy through regulated UK online clinics. There is no authorised retatrutide product for any UK prescriber to prescribe. Products currently sold as retatrutide in the UK exist entirely outside the regulated medicines system.
If Eli Lilly’s US legal action is successful, it may reduce the supply of grey-market retatrutide globally, including products that reach UK buyers. That would not mean legitimate retatrutide had become available — it would simply mean one unregulated supply route had been disrupted.
The more important point for UK readers is this: the trial results that made retatrutide so talked-about were generated using Eli Lilly’s pharmaceutical-grade compound under carefully controlled research conditions. There is no verified basis for assuming that products sold through unregulated online channels contain the same substance at the same strength or purity.
For those interested in weight-loss treatment now, the currently authorised and privately available options in the UK include Mounjaro and Wegovy, both of which are available through regulated clinics with a valid prescription. Our weight loss jabs and pills compared guide sets out what is genuinely available, the evidence behind each treatment, and how they differ. If cost is a consideration, our Mounjaro UK price comparison and Wegovy UK price comparison pages track current pricing across regulated providers.
Retatrutide’s Phase 3 trials are ongoing. If the results support an application and Eli Lilly submits to the MHRA, a formal authorisation process would follow — but no confirmed UK approval or launch date has been announced. Until an authorised version exists, there is no regulated route to access it in the UK.
Frequently Asked Questions
Is retatrutide legal to buy in the UK?
There is currently no MHRA-authorised retatrutide product in the UK. Products sold as retatrutide through online or unregulated channels are not licensed medicines and have not been approved for use by any UK regulator. The MHRA has issued broader warnings about unlicensed injectable products. The legal position for individual buyers can be complex, but there is no regulated route to purchase or receive a retatrutide prescription in the UK at this time.
Does the Eli Lilly lawsuit affect UK buyers directly?
The lawsuit was filed in a US federal court and names US-based defendants. It does not directly create new UK legal obligations for individual consumers. However, if the case disrupts supply chains, UK buyers who have been sourcing products labelled as retatrutide from these or connected companies could find supply affected. It also reinforces that the companies behind these products are not authorised manufacturers or distributors of any approved medicine.
When will retatrutide be available in the UK through legitimate channels?
No confirmed timeline has been announced. Eli Lilly’s Phase 3 TRIUMPH trial programme is ongoing. Approval would require a successful regulatory submission to the MHRA, followed by a formal assessment. Any predictions about timing are speculation at this stage. We will report on verified regulatory developments as they happen.
Are products sold as retatrutide online safe to use?
The identity, purity, strength and quality of products sold as retatrutide through unregulated channels cannot be reliably verified. No UK regulatory authority has assessed or approved these products. The MHRA advises against using unlicensed injectable medicines sourced outside the regulated supply chain. Anyone with concerns about a product they have already used should speak to a healthcare professional.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Get the UK peptide medicine briefing in your inbox.
Free weekly. No spam. Unsubscribe any time.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment. Information correct at time of publication. The Peptide Brief updates articles when guidance changes.
